N	Concordance
1	ministered with the uroprotectant agent mesna. Ifosfamide also requires hepatic 
2	cognized the efficacy of ifosfamide and mesna in the treatment of patients with 
3	xicity following intrathecal MTX and/or mesna before and after cyclophosphamide
4	his complication. Upon renal excretion, mesna (mercaptoethane sulfonate) is hydr
5	 latin; the combinations of ifosfamide, mesna, and etoposide [6,7] and of cispla
6	  consisting  of alternating courses of mesna, ifosfamide, mitoxantrone, and  et
7	onship between and urinary excretion of mesna and dimesna also was examined by c
8	t difference in the pharmacokinetics of mesna between patients who developed hem
9	osfamide with the urothelial protectant mesna induced a 20 percent response rate
10	 2 oral cyclophosphamide), allergies to mesna (2). None of the women at risk had